Lecia V Sequist
机构: Professor of Medicine, Harvard Medical School and Massachusetts General Hospital
每年引用次数
引用次数
引用: 78,900
H-指数: 113
I10-指数 : 308
出版物: 600
Revolving Door of Histologic Transformation—Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde
Michael Wysota , Saeed Asiry , Yitzhak Goldstein , Lecia V. Sequist
JTO Clinical and Research Reports 2 ( 2) 100128
2021
Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations
Andrew J. Piper-Vallillo , Meghan J. Mooradian , Catherine B. Meador , Beow Y. Yeap
JTO Clinical and Research Reports 2 ( 1) 100124
2021
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
Mizuki Nishino , Suzanne E. Dahlberg , Linnea E. Fulton , Subba R. Digumarthy
Academic Radiology 23 ( 3) 329 -336
24
2016
Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗
Andrew J. Piper-Vallillo , Lecia V. Sequist
JACC: CardioOncology 1 ( 2) 179 -181
2019
A New BATTLE in the Evolving War on Cancer
Lecia V. Sequist , Alona Muzikansky , Jeffrey A. Engelman
Cancer Discovery 1 ( 1) 14 -16
11
2011
Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers
Hiu Wing Cheung , Jinyan Du , Jesse S. Boehm , Frank He
Cancer Discovery 1 ( 7) 608 -625
99
2011
BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors
Jeffrey A Engelman , Anthony C Faber , Rakesh K Jain , Dora Dias Santagata
Cancer Discovery 1 ( 4) 352 -365
214
2011
Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
David T. Miyamoto , Richard J. Lee , Shannon L. Stott , David T. Ting
Cancer Discovery 2 ( 11) 995 -1003
231
2012
Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
James P. Sullivan , Brian V. Nahed , Marissa W. Madden , Samantha M. Oliveira
Cancer Discovery 4 ( 11) 1299 -1309
128
2014
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska , Matthew J. Niederst , Chris A. Karlovich , Heather A. Wakelee
Cancer Discovery 5 ( 7) 713 -722
328
2015
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F Gainor , Leila Dardaei , Satoshi Yoda , Luc Friboulet
Cancer Discovery 6 ( 10) 1118 -1133
517
2016
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak , Yung-Jue Bang , D. Ross Camidge , Alice T. Shaw
The New England Journal of Medicine 363 ( 18) 1693 -1703
5,120
2010
Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
Lecia V. Sequist , Jean-Charles Soria , Jonathan W. Goldman , Heather A. Wakelee
The New England Journal of Medicine 372 ( 18) 1700 -1709
768
2015
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Shyamala Maheswaran , Lecia V. Sequist , Sunitha Nagrath , Lindsey Ulkus
The New England Journal of Medicine 359 ( 4) 366 -377
2,043
2008
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Min Yu , Aditya Bardia , Ben S. Wittner , Shannon L. Stott
Science 339 ( 6119) 580 -584
2,421
2013
Update to Rociletinib Data with the RECIST Confirmed Response Rate
Lecia V. Sequist , Jean-Charles Soria , D. Ross Camidge
The New England Journal of Medicine 374 ( 23) 2296 -2297
59
2016
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
Bruce E. Johnson , David M. Jackman , Vincent A. Miller , Leigh-Anne Cioffredi
Clinical Cancer Research 15 ( 16) 5267 -5273
487
2009
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference
Thomas J Lynch , Philip D Bonomi , Charles Butts , Angela M Davies
Clinical Cancer Research 13 ( 15) 4583s -4588s
10
2007
Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
Tan Min Chin , Margaret P. Quinlan , Anurag Singh , Lecia V. Sequist
Clinical Cancer Research 14 ( 21) 6867 -6876
46
2008
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Daniel B. Costa , Kim-Son H. Nguyen , Byoung C. Cho , Lecia V. Sequist
Clinical Cancer Research 14 ( 21) 7060 -7067
136
2008